Splenic Pseudoprogression After CAR-T Therapy Detected by 18 F-FDG PET/CT in a Refractory Diffuse Large B-Cell Lymphoma Patient.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38598485.
- Also identified by DOI 10.1097/RLU.0000000000005221.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 43-year-old woman diagnosed with refractory diffuse large B-cell lymphoma was referred to chimeric antigen receptor T-cell therapy at our institution. After 3 cycles of bridging therapy, preinfusion 18 F-FDG PET/CT suggested a complete metabolic response. 18 F-FDG PET/CT 1 month after chimeric antigen receptor T-cell infusion showed 2 foci of elevated activity in the spleen, which was finally confirmed as pseudoprogression.
Medical subject headings
- Fluorodeoxyglucose F18
- Lymphoma, Large B-Cell, Diffuse
- Positron Emission Tomography Computed Tomography
- Disease Progression